Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin (Phase 2, National Institute on Aging (NIA), n=200, recruiting) — Normal aging, as well as dementias such as Alzheimer s disease, can cause changes in the brain that affect memory, attention, and thinking. Researchers want to know if regular mental tasks (cognitive training) can improve brain function in older adults.…
Investor Relations (News, Compass Pathways plc) — Compass Pathways is a biotechnology company developing COMP360 psilocybin for treatment-resistant depression and PTSD. They are leading a clinical program in TRD and executing a late-stage trial for PTSD.
New treatments for treatment-resistant depression: esketamine controversies - a narrative review. (Meta-analysis) — This narrative review examines barriers to Danish patients' timely access to new treatments for treatment-resistant depression, focusing on controversies around esketamine. Delays arise from regulatory complexity, economic constraints and scientific debate over novel psychotropics.…
Esketamine for treatment of depression in Huntington's disease: A case report. (Phase 2) — Depression and suicidal ideation are common in Huntington's disease (HD). We report a 60-year-old male with HD who suffered from treatment-resistant depression with intermittent suicidal thoughts for 20 years, irritability and apathy.…
[Intravenous ketamine in suicidal crisis : indications and patient referral]. (Meta-analysis) — Intravenous (IV) ketamine is a rapidly acting therapeutic option for the management of treatment-resistant depression and acute suicidal crisis. Unlike conventional antidepressants, its effects may occur within hours, allowing a rapid reduction in suicidal ideation and psychological distress.…
Ketamine Dose and Duration Effects in Internalizing Disorders. (Phase 2) — The dose-response profile of racemic ketamine in internalizing disorders is poorly characterized. This was a secondary analysis of outcome responses in patients with treatment-resistant depression, post-traumatic stress disorder, generalized and/or social anxiety, or obsessive-compulsive disorder.…
Rectal Prolapse Associated With Chronic Ketamine Misuse: A Report of Two Cases. (Phase 2) — Chronic ketamine misuse is a well-recognized cause of ketamine-induced uropathy (KIU), characterized by severe lower urinary tract symptoms and markedly reduced bladder capacity. Its potential association with anorectal dysfunction remains poorly described.…
Ketamine IV Classic Protocol : Five Years Follow up (Observational, Sheba Medical Center, n=11, completed) — Patients who suffer from MDD recieved ketamnie (2014-15) in open study will be addressed and there depression mood will be evaluated using the rating scale that were used in the original research. In addition time of relapse and questions about their medications and drug use will be performed.
Mitochondrial Function After Ketamine (Observational, Sheba Medical Center, n=30, recruiting) — The goal of this observational study is to learn about the role of mitochondria in response to S-ketamine. in individuals with Treatment-Resistant Depression. the Research Questions are 1.…
Ketamine for the Treatment of Opioid Use Disorder and Depression (Phase 2, Medical University of South Carolina, n=21, completed) — The purpose of the study is to examine whether an investigational medication called ketamine is able to improve treatment outcomes for concurrent opioid addiction and depression when used in conjunction with buprenorphine treatment. Study medications will be delivered twice per week for four weeks.…
Multiple Dose Pharmacokinetics of Intranasal Ketamine (Phase 1, Javelin Pharmaceuticals, n=18, completed) — This is an open label, single-center study of the pharmacokinetic and safety profile of repeat doses of PMI-150 (intranasal ketamine) 30 mg in healthy adult volunteers.
Ketamine for MS Fatigue (Observational, Alta Bates Summit Medical Center, n=21, completed) — The purpose of this study is to see whether using ketamine to increase glutamate in the prefrontal cortex can reduce Multiple Sclerosis (MS) related fatigue.…
Imaging Depression in Parkinson's Disease (Phase 2, Yale University, n=120, recruiting) — The goal of this observational study is to identify targetable neural substrates of depression in Parkinson's Disease for the first time in people with Parkinson's between the ages of 40 and 80, who are experiencing symptoms of depression.
FDA Hearing on Psychedelic Medicine Reveals a Field Divided on the Road to Approval (News) — An FDA hearing on psychedelic medicine highlighted debates regarding administration protocols, proving efficacy, and tracking safety as approvals approach. While enthusiasm exists to address unmet needs, there is a lack of consensus on execution, with discussions covering access, clinical usefulness, administration, and safety.